| General approach for the calculation of tissue to plasma partition coefficients W Schmitt Toxicology in vitro 22 (2), 457-467, 2008 | 372 | 2008 |
| Development and evaluation of a generic physiologically based pharmacokinetic model for children AN Edginton, W Schmitt, S Willmann Clinical pharmacokinetics 45, 1013-1034, 2006 | 369 | 2006 |
| Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs S Willmann, K Höhn, A Edginton, M Sevestre, J Solodenko, W Weiss, ... Journal of pharmacokinetics and pharmacodynamics 34, 401-431, 2007 | 265 | 2007 |
| A physiological model for the estimation of the fraction dose absorbed in humans S Willmann, W Schmitt, J Keldenich, J Lippert, JB Dressman Journal of medicinal chemistry 47 (16), 4022-4031, 2004 | 256 | 2004 |
| A mechanistic approach for the scaling of clearance in children AN Edginton, W Schmitt, B Voith, S Willmann Clinical pharmacokinetics 45, 683-704, 2006 | 245 | 2006 |
| PK-Sim®: a physiologically based pharmacokinetic ‘whole-body’model S Willmann, J Lippert, M Sevestre, J Solodenko, F Fois, W Schmitt Biosilico 1 (4), 121-124, 2003 | 231 | 2003 |
| Whole body physiologically-based pharmacokinetic models: their use in clinical drug development AN Edginton, FP Theil, W Schmitt, S Willmann Expert opinion on drug metabolism & toxicology 4 (9), 1143-1152, 2008 | 175 | 2008 |
| From physicochemistry to absorption and distribution: predictive mechanistic modelling and computational tools S Willmann, J Lippert, W Schmitt Expert opinion on drug metabolism & toxicology 1 (1), 159-168, 2005 | 144 | 2005 |
| Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps G Loizou, M Spendiff, HA Barton, J Bessems, FY Bois, MB d’Yvoire, ... Regulatory Toxicology and Pharmacology 50 (3), 400-411, 2008 | 131 | 2008 |
| A physiologic model for simulating gastrointestinal flow and drug absorption in rats S Willmann, W Schmitt, J Keldenich, JB Dressman Pharmaceutical research 20, 1766-1771, 2003 | 131 | 2003 |
| Toxicokinetic‐toxicodynamic modeling of quantal and graded sublethal endpoints: A brief discussion of concepts R Ashauer, A Agatz, C Albert, V Ducrot, N Galic, J Hendriks, T Jager, ... Environmental Toxicology and Chemistry 30 (11), 2519-2524, 2011 | 104 | 2011 |
| Solid‐Supported Biomolecules on Modified Silica Surfaces—A Tool for Fast Physicochemical Characterization and High‐Throughput Screening A Loidl‐Stahlhofen, J Schmitt, J Nöller, T Hartmann, H Brodowsky, ... Advanced Materials 13 (23), 1829-1834, 2001 | 89 | 2001 |
| Physiology-based pharmacokinetic modeling: ready to be used W Schmitt, S Willmann Drug Discovery Today: Technologies 1 (4), 449-456, 2004 | 65 | 2004 |
| NT‐proBNP qualifies as a surrogate for clinical end points in heart failure W Schmitt, H Rühs, R Burghaus, C Diedrich, S Duwal, T Eissing, ... Clinical Pharmacology & Therapeutics 110 (2), 498-507, 2021 | 49 | 2021 |
| The Developing Regorafenib Eye drops for neovascular Age‐related Macular degeneration (DREAM) study: an open‐label phase II trial AM Joussen, S Wolf, PK Kaiser, D Boyer, T Schmelter, R Sandbrink, ... British journal of clinical pharmacology 85 (2), 347-355, 2019 | 49 | 2019 |
| Device for the time-controlled intravenous administering of the anesthetic propofol AN Edginton, S Willmann, W Schmitt US Patent 8,038,645, 2011 | 44 | 2011 |
| Mechanistic TK/TD-model simulating the effect of growth inhibitors on Lemna populations W Schmitt, E Bruns, M Dollinger, P Sowig Ecological Modelling 255, 1-10, 2013 | 40 | 2013 |
| Device and method for calculating and supplying a drug dose S Willmann, K Höhn, A Edginton, W Schmitt US Patent App. 12/306,105, 2009 | 36 | 2009 |
| Statistical analysis of chemical transformation kinetics using Markov-Chain Monte Carlo methods L Görlitz, Z Gao, W Schmitt Environmental science & technology 45 (10), 4429-4437, 2011 | 31 | 2011 |
| Application of physiology-based pharmacokinetic and pharmacodynamic modeling to individualized target-controlled propofol infusions AN Edginton, W Schmitt, S Willmann Advances in therapy 23, 143-158, 2006 | 27 | 2006 |
Stefan WillmannBayer AG在 drwillmann.de 的电子邮件经过验证
